DOCSLIB.ORG

NLRP3 Promotes Diabetic Bladder Dysfunction and Changes in Symptom-Specific Bladder Innervation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NLRP3 Promotes Diabetic Bladder Dysfunction and Changes in Symptom-Specific Bladder Innervation 430 Diabetes Volume 68, February 2019 NLRP3 Promotes Diabetic Bladder Dysfunction and Changes in Symptom-Specific Bladder Innervation Francis M. Hughes Jr.,1,2 Nathan A. Hirshman,1 Brian M. Inouye,1 Huixia Jin,1 Eloise W. Stanton,1 Chloe E. Yun,1 Leah G. Davis,1,3 Jonathan C. Routh,1,4 and J. Todd Purves1,2,4 Diabetes 2019;68:430–440 | https://doi.org/10.2337/db18-0845 The NLRP3 inflammasome senses diabetic metabolites lacking, several experimental animal models suggest pro- and initiates inflammation implicated in diabetic com- gression from OAB to decompensation (6–8). Regardless, plications and neurodegeneration. No studies have until now, the mechanism by which the metabolic dysreg- investigated NLRP3 in diabetic bladder dysfunction ulation translates into physiological dysfunction has been (DBD), despite a high clinical prevalence. In vitro, we unclear. found that numerous diabetic metabolites activate It is now appreciated that diabetes is not just a disease NLRP3 in primary urothelial cells. In vivo, we demon- of high blood glucose but also a disease of deranged strate NLRP3 is activated in urothelia from a genetic metabolism resulting in hyperglycemia and the produc- type 1 diabetic mouse (Akita) by week 15. We then bred tion of numerous metabolites such as uric acid and free an NLRP32/2 genotype into these mice and found this fatty acids (9). These metabolites trigger inflammation blocked bladder inflammation and cystometric markers that damages susceptible tissues with a resulting loss of of DBD. Analysis of bladder innervation established function (10). Recent breakthroughs in other diabetic an NLRP3-dependent decrease in overall nerve density d fi complications (nephropathy, retinopathy, and cardiomy- and A - bers in the bladder wall along with an increase fl in C-fiber populations in the urothelia, which poten- opathy) have demonstrated this in ammation results COMPLICATIONS tially explains the decreased sense of bladder fullness from activation of the nucleotide-binding oligomeriza- – reported by patients and overactivity detected early in tion domain like receptor (NLR) NLRP3, which forms fl DBD. Together, the results demonstrate the role of a supramolecular complex known as an in ammasome NLRP3 in the genesis of DBD and suggest specific (11). NLRP3-mediated neuronal changes can produce spe- NLRP3 is the best studied of the NLR family of pattern cificDBDsymptoms. receptors. In general, pattern receptors recognize mole- cules released from damaged or dying cells (or those with deranged metabolism), known as damage (or danger)– Diabetic bladder dysfunction (DBD) affects a large pro- associated molecular patterns (DAMPs), or components portion of patients with diabetes, and there is currently no of pathogens known as pathogen-associated molecular specific therapy to treat it (1,2). With ;422 million people patterns. NLRP3 is by far the best understood NLR to with diabetes worldwide in 2014 (3) and projections that recognize DAMPs and has been implicated in many as many as 1 in 3 people will be affected in the U.S. by diseases with a sterile inflammatory component, includ- 2050 (4), this represents a highly prevalent pathological ing diabetic complications. Upon recognition of DAMPs, condition without a targeted therapy. Patients with DBD via a poorly understood mechanism, NLRP3 oligomerizes may present with urinary frequency and urgency (i.e., and triggers enucleation of an adaptor protein known as overactive bladder [OAB]), detrusor underactivity and apoptosis-associated speck-like protein C. Apoptosis- bladder decompensation (5), or some combination thereof. associated speck-like protein C, in turn, interacts with Although definitive longitudinal studies in humans are procaspase-1, which is cleaved and activated through an 1Department of Surgery, Division of Urology, Duke University Medical Center, Received 1 August 2018 and accepted 6 November 2018 Durham, NC © 2018 by the American Diabetes Association. Readers may use this article as 2 Department of Bioengineering, Clemson University, Clemson, SC long as the work is properly cited, the use is educational and not for profit, and the 3 Duke Cancer Center Biostatistics, Duke University Medical Center, Durham, NC work is not altered. More information is available at http://www.diabetesjournals. 4 Department of Pediatrics, Duke University Medical Center, Durham, NC org/content/license. Corresponding author: Francis M. Hughes Jr., [email protected] diabetes.diabetesjournals.org Hughes and Associates 431 autoproteolytic process. Caspase-1, in turn, catalyzes the were used. All animals were genotyped by Transnetyx, Inc. enzymatic maturation interleukin (IL)-1b, IL-18, and (Cordova, TN) and provided to the laboratory at ;4weeks gasderminD.GasderminDformsaporeintheplasma of age. membrane, triggering a programmed necrosis called The results of genotyping were used to assign them to pyroptosis that releases IL-1b and IL-18 that act as one of the four experimental groups. Nondiabetics are proinflammatory cytokines to initiate the inflammatory “nondiab,” and diabetics are “diab.” The groups are response. Recently, we have shown that NLRP3 plays an +/+ important role in the urinary tract of the rodent (12,13). 1. NLRP3 , nondiab: homozygote wild-type (wt) NLRP3 In the rat bladder, NLRP3 is localized to the urothelium genes, homozygote wt Ins2 genes (i.e., control mice). +/+ (14,15), where it mediates sterile inflammation in sev- 2. NLRP3 , diab: homozygote wt NLRP3 genes; hetero- eral important bladder pathologies, including bladder zygote for Akita mutation at the Ins2 gene (i.e., Akita outlet obstruction and cyclophosphamide-induced hem- diabetic control). 2/2 orrhagic cystitis (15,16). Experimental models have also 3. NLRP3 , nondiab: both NLRP3 genes knocked out, implicated NLRP3 in the response to urinary tract infec- homozygote wt Ins2 genes (i.e., NLRP3 knockout con- tions (17,18). Based on the central role for NLRP3 in trol). 2/2 other diabetic complications, coupled with its importance 4. NLRP3 ,diab:bothNLRP3 genes knocked out, in sterile cystitis, we hypothesized that NLRP3-mediated heterozygote for Akita mutation at the Ins2 gene. inflammation is a crucial element in the development of This is the experimental mouse generated for this DBD. study. To address this hypothesis, we bred a genetic mouse model of type 1 diabetes (the Akita mouse) (19) with Animals were received at 5 weeks of age. Blood glucose 2/2 anondiabeticNLRP3 strain to create a novel strain becomes high in Akita mice (200–300 mg/dL) ;4 weeks of of diabetic mice lacking NLRP3. These mice were then age and remains high thereafter (19,24). Mice were grown assessed for DBD. Mechanistically, DBD results, in to 15 weeks when DBD becomes apparent (25). No changes part, from peripheral neuropathy (20,21). Therefore, in urinary dysfunction were found at previous time points we also evaluated a role for NLRP3 in the variation (25). of nerve cell populations that could explain func- tional deficits in patients with diabetes, specifically di- In Vitro Experiments +/+ minished sensation (Ad-fibers) and bladder overactivity NLRP3 , nondiab mice (i.e., control littermates) were (C-fibers). used at 7 to 8 weeks of age. Urothelial cells were isolated (26) and plated (black-walled 96-well plates) at 50,000 RESEARCH DESIGN AND METHODS cells/well in 90 mL complete media (F-12K media, 10% low- m Experimental Approach endotoxin dialyzed FBS, 10 mol/L nonessential amino acids m Our approach in this study is three-pronged: 1) in vitro [all from HyClone Laboratories, Logan, UT], 1.0 g/mL m analysis of the activation of the inflammasome in normal hydrocortisone [Sigma-Aldrich, St. Louis, MO], 10 g/mL m mouse urothelia by diabetic-associated DAMPs; 2) in vivo insulin, 5 g/mL transferrin, and 6.7 ng/mL selenium urinary function (cystometry) in diabetic mice with a ge- [Gibco, Gaithersburg, MD]). Following a 24-h incubation m netic deletion of NLRP3; and 3) quantitation of nerve (37°C,95%air/5%CO2), DAMPs (10 L) were added densities in the bladders of these mice to assess potential and incubated as indicated. One hour prior to harvest, changes in specific nerves thought to mediate specific 1.25 mmol/L ATP was added to untreated wells. In stud- DBD symptoms. ies that examined ATP doses, cells were plated for 24 h and then treated with 1 mg/mL lipopolysaccharide (LPS) Animals (Escherichia coli 055:B5; Sigma-Aldrich) in PBS or PBS All protocols adhere to the National Institutes of Health alone for 24 h before treatment with the indicated doses Guide for the Care and Use of Laboratory Animals and were of ATP for 1 h. Caspase-1 activity was then measured as approved by the Institutional Animal Care and Use Com- previously described (14). Control florescence (0 mmol/L mittee at Duke University Medical Center. Founder mice DAMP) was subtracted from all wells and results nor- from The Jackson Laboratory (Bar Harbor, ME) consisted malized to the ATP response (except for the ATP dose- of Akita (C57BL/6J-Ins2Akita/J mice; stock number response studies). 2/2 003548) (22) and NLRP3 (B6.129S6-Nlrp3tm1Bhk/J (stock number 021302) mice (23). Although the strain Histological Preparation 2/2 of origin for the NLRP3 mice (129S6/SvEvTac) is Bladders were formalin-fixed and paraffin-embedded in different from the Akita background (C57BL/6J), these a transverse orientation. Sections (5 mm) from the lower mice have been backcrossed to C57BL/6J for .11 gen- third of the bladder were stained with anti-NLRP3 erations (https://www.jax.org/). Mice were bred by the (1:100) (catalog number LS-C334192; LifeSpan BioScien- Breeding Core Facility at Duke University through an ces, Inc., Seattle, WA), anti-PGP9.5 (1:200) (catalog num- independently approved protocol, and only female mice ber 381000; Thermo Fisher Scientific, Waltham, MA), 432 NLRP3 Promotes Diabetic Bladder Dysfunction Diabetes Volume 68, February 2019 anti-neurofilament 200 (1:200) (NF-200; Ad-fibers; cat- to measure voided volume. The catheter was connected alog number N4142; Sigma-Aldrich), or anti–calcitonin to a syringe pump via an in-line pressure transducer gene-related peptide (1:80) (CGRP; C-fibers; catalog num- and sterile saline infused at 15 mL/min for 60–120 min.
Load more

Recommended publications
  • 35 Disorders of Purine and Pyrimidine Metabolism
    35 Disorders of Purine and Pyrimidine Metabolism Georges van den Berghe, M.- Françoise Vincent, Sandrine Marie 35.1 Inborn Errors of Purine Metabolism – 435 35.1.1 Phosphoribosyl Pyrophosphate Synthetase Superactivity – 435 35.1.2 Adenylosuccinase Deficiency – 436 35.1.3 AICA-Ribosiduria – 437 35.1.4 Muscle AMP Deaminase Deficiency – 437 35.1.5 Adenosine Deaminase Deficiency – 438 35.1.6 Adenosine Deaminase Superactivity – 439 35.1.7 Purine Nucleoside Phosphorylase Deficiency – 440 35.1.8 Xanthine Oxidase Deficiency – 440 35.1.9 Hypoxanthine-Guanine Phosphoribosyltransferase Deficiency – 441 35.1.10 Adenine Phosphoribosyltransferase Deficiency – 442 35.1.11 Deoxyguanosine Kinase Deficiency – 442 35.2 Inborn Errors of Pyrimidine Metabolism – 445 35.2.1 UMP Synthase Deficiency (Hereditary Orotic Aciduria) – 445 35.2.2 Dihydropyrimidine Dehydrogenase Deficiency – 445 35.2.3 Dihydropyrimidinase Deficiency – 446 35.2.4 Ureidopropionase Deficiency – 446 35.2.5 Pyrimidine 5’-Nucleotidase Deficiency – 446 35.2.6 Cytosolic 5’-Nucleotidase Superactivity – 447 35.2.7 Thymidine Phosphorylase Deficiency – 447 35.2.8 Thymidine Kinase Deficiency – 447 References – 447 434 Chapter 35 · Disorders of Purine and Pyrimidine Metabolism Purine Metabolism Purine nucleotides are essential cellular constituents 4 The catabolic pathway starts from GMP, IMP and which intervene in energy transfer, metabolic regula- AMP, and produces uric acid, a poorly soluble tion, and synthesis of DNA and RNA. Purine metabo- compound, which tends to crystallize once its lism can be divided into three pathways: plasma concentration surpasses 6.5–7 mg/dl (0.38– 4 The biosynthetic pathway, often termed de novo, 0.47 mmol/l). starts with the formation of phosphoribosyl pyro- 4 The salvage pathway utilizes the purine bases, gua- phosphate (PRPP) and leads to the synthesis of nine, hypoxanthine and adenine, which are pro- inosine monophosphate (IMP).
    [Show full text]
  • Pro-Aging Effects of Xanthine Oxidoreductase Products
    antioxidants Review Pro-Aging Effects of Xanthine Oxidoreductase Products , , Maria Giulia Battelli y , Massimo Bortolotti y , Andrea Bolognesi * z and Letizia Polito * z Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Alma Mater Studiorum, University of Bologna, Via San Giacomo 14, 40126 Bologna, Italy; [email protected] (M.G.B.); [email protected] (M.B.) * Correspondence: [email protected] (A.B.); [email protected] (L.P.); Tel.: +39-051-20-9-4707 (A.B.); +39-051-20-9-4729 (L.P.) These authors contributed equally. y Co-last authors. z Received: 22 July 2020; Accepted: 4 September 2020; Published: 8 September 2020 Abstract: The senescence process is the result of a series of factors that start from the genetic constitution interacting with epigenetic modifications induced by endogenous and environmental causes and that lead to a progressive deterioration at the cellular and functional levels. One of the main causes of aging is oxidative stress deriving from the imbalance between the production of reactive oxygen (ROS) and nitrogen (RNS) species and their scavenging through antioxidants. Xanthine oxidoreductase (XOR) activities produce uric acid, as well as reactive oxygen and nitrogen species, which all may be relevant to such equilibrium. This review analyzes XOR activity through in vitro experiments, animal studies and clinical reports, which highlight the pro-aging effects of XOR products. However, XOR activity contributes to a regular level of ROS and RNS, which appears essential for the proper functioning of many physiological pathways. This discourages the use of therapies with XOR inhibitors, unless symptomatic hyperuricemia is present.
    [Show full text]
  • Thermostable and Long-Circulating Albumin-Conjugated Arthrobacter Globiformis Urate Oxidase
    pharmaceutics Article Thermostable and Long-Circulating Albumin-Conjugated Arthrobacter globiformis Urate Oxidase Byungseop Yang and Inchan Kwon * School of Materials Science and Engineering, Gwangju Institute of Science and Technology (GIST), Gwangju 61005, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-62-715-2312 Abstract: Urate oxidase derived from Aspergillus flavus has been investigated as a treatment for tumor lysis syndrome, hyperuricemia, and gout. However, its long-term use is limited owing to potential immunogenicity, low thermostability, and short circulation time in vivo. Recently, urate oxidase isolated from Arthrobacter globiformis (AgUox) has been reported to be thermostable and less immunogenic than the Aspergillus-derived urate oxidase. Conjugation of human serum albumin (HSA) to therapeutic proteins has become a promising strategy to prolong circulation time in vivo. To develop a thermostable and long-circulating urate oxidase, we investigated the site-specific conjugation of HSA to AgUox based on site-specific incorporation of a clickable non-natural amino acid (frTet) and an inverse electron demand Diels–Alder reaction. We selected 14 sites for frTet incorporation using the ROSETTA design, a computational stability prediction program, among which AgUox containing frTet at position 196 (Ag12) exhibited enzymatic activity and thermostability comparable to those of wild-type AgUox. Furthermore, Ag12 exhibited a high HSA conjugation yield without compromising the enzymatic activity, generating well-defined HSA-conjugated AgUox (Ag12-HSA). In mice, the serum half-life of Ag12-HSA was approximately 29 h, which was roughly Citation: Yang, B.; Kwon, I. 17-fold longer than that of wild-type AgUox. Altogether, this novel formulated AgUox may hold Thermostable and Long-Circulating enhanced therapeutic efficacy for several diseases.
    [Show full text]
  • Alternative Pathways of Glucose Metabolism II. Nucleotides from The
    Alternative Pathways of Glucose Metabolism II . Nucleotides from the Acid-soluble Fraction of Normal and Tumor Tissues and Studies on Nucleic Acid Synthesis in Tumors*t HANNS SCHMITZ4 VAN R. POTTER, ROBERT B. HTJRLBERT,@ AND DWAIN M. WHITE (McArdie Memovial Laboratory, the Medical School, University of Wisconain, Madison, WI..) The first paper (18) in this series on the alterna MATERIALS AND METHODS tive pathways of glucose metabolism established The present study has involved the measure the fact that radioactivity from glucose-i-C'4 was ment of the specific activities of the free 5' mono-, readily incorporated into the pentose moiety of the di-, and triphosphates of adenosine, guanosine, ribonucleic and desoxyribonucleic acids of Flexner cytidine, and uridine from the acid-soluble extract Jobling tumors in rats, and described the over-all of tumor tissue in relation to the specific activities distribution of radioactivity in the acid-soluble of the corresponding nucleotides that were oh and acid-insoluble fractions of tumor and liver tis tamed by chemical or enzymatic hydrolysis of the sue at various time periods. The acid-soluble frac nucleic acids from the same tissue samples, at tion of tissue contains an appreciable amount of specified time intervals after the injection of glu free nucleotides which are possible intermediary cose-1-C'4. The experimental plan corresponds compounds in the synthesis of the nucleic acids exactly to that described in the preceding paper; (6, 7, 8, 9, 13, 16). It was noted (18) that as the C'4 many of
    [Show full text]
  • Low Uric Acid Diet Diet FAQ's What Is Uricvs Acid? Uric Acid Is a Byproduct of Purines (PYUR-Eenz)
    o ?? ou need t Y our reduce y Uric Acid! Understanding the Low Uric Acid Diet Diet FAQ's What is Uricvs Acid? Uric acid is a byproduct of purines (PYUR-eenz). Purines are naturally occurring substances and are found in many food items. As purines are broken down in the body, they are eliminated as uric acid. What does Uric Acid have to do with CKD? Normally, uric acid passes through the kidneys and is excreted in urine. However, when the kidneys cannot process all of the uric acid, hyperuricemia, or elevated uric acid in the blood, may develop. Recent research has determined that approximately 10% of Americans with Chronic Kidney Disease (CKD) also have gout, and if left untreated, can further worsen kidney function. Why do I need a diet that reduces Uric Acid? When your kidneys are not functioning properly, they do not filter out uric acid properly, thus potentially leading to a number of health issues. Elevated hyperuricemia (elevated uric acid levels) may cause: • Worsening of kidney function • Flare up of gout • Damage to affected joints Diet Do's and Don'ts Do Don't DO Don't Do Don't Exercise: even 1 minute of moderate to brisk Don’t take baker’s yeast or brewer’s yeast as a walking is helpful supplement Drink 8-12 cups o f fluid daily, this may help reduce Don't drink ( or try to limit) alcohol. Alcohol increases kidney stone formation and decrease uric acid purine production, thus further worsening crystals hyperuricemia Foods to limit Limit meat to 3 ounces per meal Limit high fat foods, such as salad dressings, ice cream, fried foods, & gravies.
    [Show full text]
  • Study of Purine Metabolism in a Xanthinuric Female
    Study of Purine Metabolism in a Xanthinuric Female MICHAEL J. BRADFORD, IRWIN H. KRAKOFF, ROBERT LEEPER, and M. EARL BALis From the Sloan-Kettering Institute, Sloan-Kettering Division of Cornell University Graduate School of Medical Sciences, and the Department of Medicine of Memorial and James Ewing Hospitals, New York 10021 A B S TR A C T A case of xanthinuria is briefly de- Case report in brief. The patient is a 62 yr old scribed, and the results of in vivo studies with Puerto Rican grandmother, whose illness is de- 4C-labeled oxypurines are discussed. The data scribed in detail elsewhere.' Except for mild pso- demonstrate that the rate of the turnover of uric riasis present for 30 yr, she has been in good acid is normal, despite an extremely small uric health. On 26 June 1966, the patient was admitted acid pool. Xanthine and hypoxanthine pools were to the Second (Cornell) Medical Service, Bellevue measured and their metabolism evaluated. The Hospital, with a 3 day history of pain in the right bulk of the daily pool of 276 mg of xanthine, but foot and fever. The admission physical examina- only 6% of the 960 mg of hypoxanthine, is ex- tion confirmed the presence of monoarticular ar- creted. Thus, xanthine appears to be a metabolic thritis and mild psoriasis. The patient's course in end product, whereas hypoxanthine is an active the hospital was characterized by recurrent fevers intermediate. Biochemical implications of this find- to 104°F and migratory polyarthritis, affecting ing are discussed. both ankles, knees, elbows, wrists, and hands over a 6 wk period.
    [Show full text]
  • Purine and Pyrimidine Metabolism in Human Epidermis* Jean De Bersaques, Md
    THE JOURNAL OP INVESTIGATIVE DERMATOLOGY Vol. 4s, No. Z Copyright 1957 by The Williams & Wilkins Co. Fri nte,1 in U.S.A. PURINE AND PYRIMIDINE METABOLISM IN HUMAN EPIDERMIS* JEAN DE BERSAQUES, MD. The continuous cellular renewal occurring inthine, which contained 5% impurity, and for uric the epidermis requires a very active synthesisacid, which consisted of 3 main components. The reaction was stopped after 1—2 hours in- and breakdown of nuclear and cytoplasmiecubation at 37° and the products were spotted on nucleic acids. Data on the enzyme systemsWhatman 1 filter paper sheets. According to the participating in these metabolic processes arereaction products expected, a choice was made of rather fragmentary (1—9) and some are, inat least 2 among the following solvents, all used terms of biochemical time, in need of up- in ascending direction: 1. isoamyl alcohol—5% Na2HPO4 (1:1), dating. In some other publications (10—18), 2. water-saturated n-butanol, the presence and concentration of various in- 3. distilled water, termediate products is given. 4. 80% formic acid—n-hutanol——n-propanol— In this paper, we tried to collect and supple- acetone—30% trichloro-aeetic acid (5:8:4: ment these data by investigating the presence 5:3), 5. n-butanol——4% boric acid (43:7), or absence in epidermis of enzyme systems 6. isobutyrie acid—water—ammonia 0.880—ver- that have been described in other tissues. sene 0.1M(500:279:21:8), This first investigation was a qualitative one, 7. upper phase of ethyl acetate—water—formic and some limitations were set by practical acid (12:7:1), 8.
    [Show full text]
  • Hypoxanthine, Xanthine, and Uric Acid Concentrations in Plasma
    003 1 -3998/93/3406-0767$03.00/0 PEDIATRIC RESEARCH Vol. 34, No. 6, 1993 Copyright O 1993 International Pediatric Research Foundation, Inc. Printed in U.S. A. Hypoxanthine, Xanthine, and Uric Acid Concentrations in Plasma, Cerebrospinal Fluid, Vitreous Humor, and Urine in Piglets Subjected to Intermittent Versus Continuous Hypoxemia LAURITZ STOLTENBERG, TERJE ROOTWELT, STEPHANIE BYASAETER, TORLEIV 0. ROGNUM, AND OLA D. SAUGSTAD Department of Pediatric Research [L.S.. T.R..S.0.. O.D.S.].Institute ofSurgica1 Research [L.S.. T.R.],and Insritute of Forensic Medicine [L.S., T.O.R.],The National Hospital, 0027 Oslo 1, Norway ABSTRACT. Infants with sudden infant death syndrome compared with 20% in infants that die suddenly or unexpectedly have higher hypoxanthine (Hx) concentrations in their from other causes (4). It was concluded in this study that SIDS, vitreous humor than infants with respiratory distress syn- in most cases, is probably not a sudden event but may be drome and other infant control populations. However, pre- preceded by a relatively long period of respiratory failure and vious research on piglets and pigs applying continuous hypoxia. However, previous experiments on piglets applying hypoxemia has not been able to reproduce the concentra- different degrees and durations of CH have not been able to tions observed in infants with sudden infant death syn- reproduce equally high vitreous humor Hx values as observed in drome. To test whether intermittent hypoxemia could, in SIDS (5). Perhaps the higher Hx concentration formed in vitre- part, explain this observed difference, Hx, xanthine (X), ous humor of SIDS victims is due to the fact that these infants and uric acid were measured in vitreous humor, urine, suffer repeated episodes of hypoxemia before they die.
    [Show full text]
  • Quercetin Lowers Plasma Uric Acid in Pre-Hyperuricaemic Males: a Randomised, Double-Blinded, Placebo-Controlled, Cross-Over Trial
    This is a repository copy of Quercetin lowers plasma uric acid in pre-hyperuricaemic males: a randomised, double-blinded, placebo-controlled, cross-over trial. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/92907/ Version: Accepted Version Article: Shi, Y and Williamson, G (2016) Quercetin lowers plasma uric acid in pre-hyperuricaemic males: a randomised, double-blinded, placebo-controlled, cross-over trial. British Journal of Nutrition, 115 (5). pp. 800-806. ISSN 0007-1145 https://doi.org/10.1017/S0007114515005310 Reuse Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher’s website. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ 1 1 Quercetin lowers plasma uric acid in pre-hyperuricemic males: a randomized, 2 double-blinded, placebo-controlled, cross-over trial 3 Yuanlu Shi1, Gary Williamson1* 4 1 School of Food Science and Nutrition, University of Leeds, Leeds LS2 9JT, UK 5 Running Head: Quercetin lowers uric acid in humans 6 Key words: quercetin, bioequivalence, dietary supplement, human 7 * Corresponding Author: Gary Williamson, Tel: +44(0)113-343-8380; Email: 8 [email protected] 9 Clinical trial registration: The study was registered on ClinicalTrials.gov (identifier 10 number NCT01881919).
    [Show full text]
  • Nucleo'de)Metabolism) (Chapter)23)) INTRODUCTION)TO)NUCLEIC)ACIDS)
    BIOCH 765: Biochemistry II Spring 2014 Nucleo'de)Metabolism) (Chapter)23)) Jianhan)Chen) Office)Hour:)MF)1:30B2:30PM,)Chalmers)034) Email:)[email protected]) Office:)785B2518) INTRODUCTION)TO)NUCLEIC)ACIDS) (c))Jianhan)Chen) 2) Eukaryo'c)cell) 3 Genome)is)believed)to)define)a)species) 4 Nucleic)Acids) • Polymer(of( nucleotides:(highly( flexible((compared( to(peptides)( • Nucleic(acids(are( universal(in(living( things,(as(they(are( found(in(all(cells( and(viruses.( • Nucleic(acids(were( first(discovered(by( Friedrich(Miescher( in(1871.( (c))Jianhan)Chen) 5 Building)Blocks)of)Nucleo'des) • Phosphate(group(+(pentose(carbohydrate(+( base((nitrogenGcontaining(heterocyclic(ring)( • Deoxyribonucleic(acid((DNA):(A/G/C/T( • Ribonuclei(acid((RNA):(A/G/C/U( Nucleotide nucleobase 6 Nucleo'des)have)many)roles) • Building(blocks(of(the(nucleic(acid(polymers(RNA(and( DNA.( • Energy(transfer(or(energy(coupling(to(drive(biosynthesis( and(other(processes((muscle(contraction,(transport,(etc).( • Oxidation(reduction(reactions.( • Intracellular(signaling.( ATP 7 Pentose)sugars) Base Phosphate sugar • The(pentose(sugar(in(the(nucloetide(is(either(ribose(or( deoxyribose.( ( – The(base(is(added(at(the(1(position(and(phosphates(are(added(at( the(5(position.( – Most(nucleotides,(including(those(incorporated(into(RNA,(contain( ribose.( – 2’GOH(reduced(to(–H(in(deoxynucleotides( – 3’GOH(participates(in(forming(phosphodiester(linkage( – Deoxynucleotides(are(exclusively(used(for(DNA(synthesis.( 8 Nucleo'de)forma'on) O ║ H N The base is added at the 1 6 N position and phosphates
    [Show full text]
  • Very Low Density Lipoprotein in Patients with Gout
    Ann Rheum Dis: first published as 10.1136/ard.44.6.390 on 1 June 1985. Downloaded from Annals of the Rheumatic Diseases, 1985, 44, 390-394 Demonstration of an abnormality of C apoprotein of very low density lipoprotein in patients with gout D G MACFARLANE, C A MIDWINTER, P A DIEPPE, C H BOLTON, AND M HARTOG From the University Department of Medicine, Bristol Royal Infirmary, Marlborough Street, Bristol BS2 8HU, Avon SUMMARY The very low density (VLDL) apolipoproteins of 12 male patients with gout have been studied by analytical isoelectric focusing. The relative percentage distribution of the C apolipoproteins was calculated and compared with that from 12 normolipidaemic and 12 'lipid-matched' controls. In the gout patients apolipoprotein CII (apo CII) represented 19-6% of the VLDL C proteins and the CII/CIII2 ratio was 0-57. In the normolipidaemic controls apo CII represented 28*8% and in the lipid-matched controls 33*1% of VLDL apo C, and the CII/C0112 ratio approached one in each control group. These differences were significant. This suggests that a reduction in VLDL apo CII may predispose to the hypertriglyceridaemia that is commonly found in patients with gout. copyright. Key words: gout, hyperlipidaemia, apolipoprotein CII. Many studies have shown a high incidence of had been approved by the local ethical committee. hyperlipidaemia in patients with gout, commonly All their drug treatment was stopped for a period of hypertnxglyceridaemia due to raised endogenous six weeks, and they were also requested to reduce http://ard.bmj.com/ VLDL. -3 As well as lipid, VLDL particles contain their alcohol intake as much as possible and avoid B, C, and E apoproteins, and recent discoveries self medication.
    [Show full text]
  • Purine Metabolism in Adenosine Deaminase Deficiency* (Immunodeficiency/Pyrimidines/Adenine Nucleotides/Adenine) GORDON C
    Proc. Nati. Acad. Sci. USA Vol. 73, No. 8, pp. 2867-2871, August 1976 Immunology Purine metabolism in adenosine deaminase deficiency* (immunodeficiency/pyrimidines/adenine nucleotides/adenine) GORDON C. MILLS, FRANK C. SCHMALSTIEG, K. BRYAN TRIMMER, ARMOND S. GOLDMAN, AND RANDALL M. GOLDBLUM Departments of Human Biological Chemistry and Genetics and Pediatrics, The University of Texas Medical Branch and Shriners Burns Institute, Galveston, Texas 77550 Communicated by J. Edwin Seegmiller, June 1, 1976 ABSTRACT Purine and pyrimidine metabolites were MATERIALS AND METHODS measured in erythrocytes, plasma, and urine of a 5-month-old infant with adenosine deaminase (adenosine aminohydrolase, Subject. A 5-month-old boy born on December 5, 1974 with EC 3.5.4.4) deficiency. Adenosine and adenine were measured severe combined immunodeficiency was investigated. Physical using newly devised ion exchange separation techniques and examination revealed enlarged costochondral junctions and a sensitive fluorescence assay. Plasma adenosine levels were sparse lymphoid tissue (5). The serum IgG (normal values in increased, whereas adenosine was normal in erythrocytes and parentheses) was 31 mg/dl (263-713); IgM, 8 mg/dl not detectable in urine. Increased amounts of adenine were (34-138); found in erythrocytes and urine as well as in the plasma. and IgA was less than 3 mg/dl (13-71). Clq was not detectable Erythrocyte adenosine 5'-monophosphate and adenosine di- by double immunodiffusion. The blood lymphocyte count was phosphate concentrations were normal, but adenosine tri- 200-400/mm3 with 2-4% sheep erythrocyte (E)-rosettes, 12% phosphate content was greatly elevated. Because of the possi- sheep erythrocyte-antibody-complement (EAC)-rosettes, 10% bility of pyrimidine starvation, pyrimidine nucleotides (py- IgG bearing cells, and no detectable IgA or IgM bearing cells.
    [Show full text]